Mark Lappe Files 13D for Inhibrx Biosciences

TL;DR

Lappe filed a 13D on INBX - watch this.

AI Summary

Mark Lappe filed a Schedule 13D on June 3, 2024, regarding his beneficial ownership of Inhibrx Biosciences, Inc. The filing indicates a change in reporting as of May 29, 2024, and Lappe's address is listed as c/o Inhibrx Biosciences, Inc. in La Jolla, California.

Why It Matters

This filing signals a potential shift in control or significant stakeholding by Mark Lappe in Inhibrx Biosciences, which could influence the company's strategic direction.

Risk Assessment

Risk Level: medium — A Schedule 13D filing indicates a significant ownership stake and potential for activist involvement, which can introduce uncertainty and volatility.

Key Players & Entities

• Mark Lappe (person) — Filing person
• Inhibrx Biosciences, Inc. (company) — Subject company
• 0000950142-24-001548 (filing_id) — Accession number for the filing
• 45720N103 (cusip) — CUSIP number for Inhibrx Biosciences, Inc. common stock

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• eh240491006_13d-lappe.htm (SC 13D) — 38KB
• 0000950142-24-001548.txt ( ) — 40KB

Security and Issuer

Item 1. Security and Issuer. This Schedule 13D (this “ Schedule 13D ”) relates to the shares of the common stock, par value $0.0001 per share (the “ Common Stock ”), of Inhibrx Biosciences, Inc., a Delaware corporation (the “ Issuer ”). The address of the Issuer’s principal executive office is 11025 N. Torrey Pines Road, Suite 140, La Jolla, California 92037.

Identity and Background

Item 2. Identity and Background. (a) This Schedule 13D is being filed on behalf of Mark P. Lappe (“ Mr. Lappe ”), as an individual. (b) The principal business address for Mr. Lappe is c/o Inhibrx Biosciences, Inc., 11025 N. Torrey Pines Road, Suite 140, La Jolla, California 92037. (c) Mr. Lappe is the Chief Executive Officer, President and Chairman of the Board of Directors of the Issuer. (d) During the last five years, Mr. Lappe has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years, Mr. Lappe has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Mr. Lappe is a citizen of the United States of America.

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration. On May 30, 2024, Inhibrx, Inc., a Delaware corporation, completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 22, 2024 (the “Merger Agreement”), by and among Aventis Inc., a Pennsylvania corporation (“Parent”) and wholly owned subsidiary of Sanofi S.A. (“Sanofi”), Art Acquisition Sub, Inc. (“Merger Sub”) and Inhibrx, Inc. Pursuant to the Merger Agreement, Merger Sub merged with and into Inhibrx, Inc. (the “Merger”), with Inhibrx, Inc. surviving the Merger as a wholly owned subsidiary of Parent. In connection with and as a condition to the Merger, on May 29, 2024, Inhibrx, Inc. completed the previously announced transactions pursuant to the Separation and Distribution Agreement, dated as of January 22, 2024 (the “Separation and Distribution Agreement”), by and among Inhibrx, Inc. and the Issuer, pursuant to, which, among other things, Inhibrx, Inc. distributed to its stockholders as of the distribution record date of May 17, 2024, 92% of the issued and outstanding shares of common stock of the Issuer, on a pro rata basis (the “Spin-Off”), at a ratio of one share of Common Stock for every four (4) shares of Inhibrx, Inc.’s issued and outstanding common stock, par value $0.0001 per share, held on the distribution record date. Mr. Lappe acquired the shares of Common Stock reported in this Schedule 13D in the Spin-Off.

Purpose of Transaction

Item 4. Purpose of Transaction. The information set forth under Item 3 above is incorporated by reference herein. CUSIP No. 45720N103 SCHEDULE 13D Page 4 of 6 Mr. Lappe acquired the shares of the Common Stock reported in this Schedule 13D in the Spin-Off and holds such shares for investment purposes and intends to review such investment in the Issuer on a continuing basis. Consistent with such purposes, Mr. Lappe may engage in communications with, without limitation, one or more stockholders of the Issuer, management of the Issuer and/or one or more members of the board of directors of the Issuer and may make suggestions concerning the Issuer’s operations, prospects, business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, the composition of the board of directors of the Issuer and such other matters as Mr. Lappe may deem relevant to his investment in the Issuer. Mr. Lappe expects that he will, from time to time, review his investment position in the shares of the Common Stock or the Issuer and may, depending on the Issuer’s performance and other market conditions, increase or decrease his investment position in the Common Stock. Mr. Lappe may, from time to time, make additional purchases of shares of the Common Stock either in the open market or in privately negotiated transactions, depending upon his evaluation of the Issuer’s business, prospects, financial condition and results of operations, the market for the Common Stock, other opportunities available to Mr. Lappe , general economic conditions, stock market conditions and other factors. Depending upon the factors noted above, Mr. Lappe may also decide to hold or dispose of all or part of his investment in the Common Stock and/or enter into derivative transactions with institutional counterparties with respect to the Issuer’s securities, including the Common Stock. Any actions Mr. Lappe might undertake may be made at

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. (a) (b) See the cover page. (c) The information set forth under Item 3 above is incorporated by reference herein. (d) Not applicable. (e) Not applicable. CUSIP No. 45720N103 SCHEDULE 13D Page 5 of 6

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None.

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits. None. CUSIP No. 45720N103 SCHEDULE 13D Page 6 of 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: June 3, 2024 Mark Lappe /s/ Mark Lappe

View Full Filing

View this SC 13D filing on SEC EDGAR